|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
¶ – Release Delayed to: 7/31/06 ·As Of Filer Filing For·On·As Docs:Size Issuer Agent 8/11/05 Antares Pharma, Inc. POS AM¶ 3:331K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: POS AM Post Effective Amendment No. 2 on Form S-3 to Form HTML 278K
S-2
3: COVER ¶ Comment-Response or Cover Letter to the SEC HTML 9K
2: EX-23.2 Consent of Kpmg LLP HTML 5K
| SEC Cover Letter |
ANTARES PHARMA, INC.
707 EAGLEVIEW BOULEVARD
EXTON, PENNSYLVANIA 19341
VIA FACSIMILE AND FEDERAL EXPRESS AND TRANSMITTED VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
450 Fifth Street, Northwest
Washington, DC 20549
Attention: Jay Mumford, Esq.
| Re: | Antares Pharma, Inc. |
Form S-3 (“Amendment”)
Filed July 22, 2005
Commission File No. 333-109114
Dear Mr. Mumford:
On behalf of Antares Pharma, Inc., and pursuant to your conversation with our counsel at Leonard, Street and Deinard Professional Association, attached are certain pages of the above-captioned Amendment, marked to reflect changes made thereto based on the comments contained in the letter to the company, dated of even date herewith, from Russell Mancuso, Branch Chief, United States Securities and Exchange Commission. As you know, our hope is to have the Registration Statement on Form S-3 we originally filed on July 22, 2005 (“Registration Statement”) declared effective prior to the required filing of our Quarterly Report on Form 10-Q for the period ended June 30, 2004, which is due on Monday, August 15, 2005. Presuming that the changes reflected in the attached are acceptable, we are prepared to immediately file the Amendment, this correspondence and a related acceleration request via EDGAR.
The following information is provided on behalf of the Antares Pharma in response to Mr. Mancuso’s letter referred to above, a copy of which is attached to the facsimile and Federal Express copy of this letter. We have reproduced below the comments contained in Mr. Mancuso’s letter, together with our responses (in indented, boldface type).
Facing Page
| 1. | If your filing is based on Rule 429, please say so and identify the appropriate registration statement in accordance with the requirements of Rule 429(b). |
We have complied with this comment.
United States Securities and Exchange Commission
Division of Corporation Finance
Attention: Jay Mumford, Esq., Staff Attorney
Page 2
Prospectus
| 2. | We note your reference on page 18 to information in previous prospectuses. Information in prospectuses may not be incorporated by reference to a prior prospectus. Instead, you must file a prospectus that includes all of the information that would be required in a prospectus relating to all offerings that the rule 429 prospectus covers, including a complete, current selling shareholders table. |
We have also complied with this comment.
Again, we sincerely appreciate your prompt attention to this matter. If you have any questions, please do not hesitate to call me at (610) 458-0275 or our counsel, Jeffrey Cotter, at (612) 335-1444.
Very truly yours,
| /S/ LAWRENCE M. CHRISTIAN |
| Lawrence M. Christian |
| Chief Financial Officer |
Enclosures
| This ‘POS AM’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 8/15/05 | 10-Q | |||
| Filed on: | 8/11/05 | |||
| 7/22/05 | POS AM | |||
| 6/30/04 | 10-Q | |||
| List all Filings | ||||